CL2020002223A1 - Anticuerpos anti-pd-l1 y usos de los mismos - Google Patents
Anticuerpos anti-pd-l1 y usos de los mismosInfo
- Publication number
- CL2020002223A1 CL2020002223A1 CL2020002223A CL2020002223A CL2020002223A1 CL 2020002223 A1 CL2020002223 A1 CL 2020002223A1 CL 2020002223 A CL2020002223 A CL 2020002223A CL 2020002223 A CL2020002223 A CL 2020002223A CL 2020002223 A1 CL2020002223 A1 CL 2020002223A1
- Authority
- CL
- Chile
- Prior art keywords
- seq
- antibodies
- fragments
- cdr1
- cdr2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan anticuerpos anti-PD-1 o fragmentos de los mismos. Los anticuerpos o fragmentos de los mismos se unen específicamente al dominio C de inmunoglobulina de la proteína PD-L1. En varios ejemplos, los anticuerpo o fragmentos de los mismos incluyen una VH CDR1 de la SEQ ID NO: 1, una VH CDR2 de la SEQ ID NO: 116, una VH CDR3 de la SEQ ID NO: 117, una VL CDR1 de la SEQ ID NO: 4, una VL CDR2 de la SEQ ID NO: 5, y una VL CDR3 de la SEQ ID NO: 6, o variantes de cada uno de los mismos. Se proporcionan métodos de uso de los anticuerpos o fragmentos de los mismos para tratar y diagnosticar enfermedades tales como cáncer y enfermedades infecciosas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018081079 | 2018-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020002223A1 true CL2020002223A1 (es) | 2021-01-29 |
Family
ID=68060946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002223A CL2020002223A1 (es) | 2018-03-29 | 2020-08-28 | Anticuerpos anti-pd-l1 y usos de los mismos |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11220546B2 (es) |
| EP (1) | EP3589660A4 (es) |
| JP (1) | JP7124257B2 (es) |
| KR (2) | KR102177931B1 (es) |
| CN (1) | CN110891975B (es) |
| AU (1) | AU2019241339B2 (es) |
| BR (1) | BR112020019827A2 (es) |
| CA (1) | CA3086434C (es) |
| CL (1) | CL2020002223A1 (es) |
| EA (1) | EA202091590A1 (es) |
| IL (1) | IL275734B (es) |
| MX (1) | MX2020007842A (es) |
| MY (1) | MY188237A (es) |
| PE (1) | PE20210377A1 (es) |
| PH (1) | PH12020551173A1 (es) |
| SG (1) | SG11202006008WA (es) |
| UA (1) | UA125918C2 (es) |
| WO (1) | WO2019185029A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6730466B2 (ja) * | 2016-06-13 | 2020-07-29 | アイ−エムエービー バイオファーマ ユーエス リミテッド | 抗ｐｄ−ｌ１抗体およびその使用 |
| WO2020020307A1 (en) * | 2018-07-25 | 2020-01-30 | I-Mab Biopharma Co., Ltd. | Anti-cd73 anti-pd-l1 bispecific antibodies |
| JP7177543B2 (ja) * | 2018-08-21 | 2022-11-24 | エービーエル バイオ インコーポレイテッド | 抗ｐｄ－ｌ１／抗ｌａｇ３二重特異性抗体およびその使用 |
| WO2021097800A1 (en) * | 2019-11-22 | 2021-05-27 | Abl Bio Inc. | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof |
| CN115643797A (zh) * | 2020-04-30 | 2023-01-24 | 天境生物科技(上海)有限公司 | 包含抗cd47抗体的药物组合物 |
| US20230287125A1 (en) * | 2020-07-28 | 2023-09-14 | Lepu Biopharma Co., Ltd. | Bifunctional molecules targeting pd-l1 and tgf-beta |
| JP7773528B2 (ja) | 2020-08-19 | 2025-11-19 | ゼンコア インコーポレイテッド | 抗ｃｄ２８組成物 |
| CN114195900B (zh) * | 2020-09-17 | 2024-02-23 | 普米斯生物技术(珠海)有限公司 | 一种抗4-1bb/pd-l1双特异性抗体及其用途 |
| CN114316045B (zh) * | 2020-09-29 | 2024-07-12 | 英诺欧奇生物医药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
| CN113234162B (zh) * | 2020-12-24 | 2022-05-13 | 四川大学华西医院 | 一种靶向cd133的嵌合抗原受体t细胞 |
| US20240301068A1 (en) * | 2021-01-08 | 2024-09-12 | Beijing Hanmi Pharmaceutical Co., Ltd. | Antibody specifically binding with pd-l1 and antigen-binding fragment of antibody |
| JP7773238B2 (ja) * | 2021-02-19 | 2025-11-19 | シャペロン インク． | Ｐｄ－ｌ１に対する単一ドメイン抗体及びその用途 |
| CN115073599B (zh) * | 2021-03-16 | 2023-04-28 | 北京天广实生物技术股份有限公司 | 结合pd-l1的抗体及其用途 |
| US12365743B2 (en) | 2022-02-23 | 2025-07-22 | Xencor, Inc. | Anti-CD28 x anti-PSMA antibodies |
| KR20240166575A (ko) * | 2022-04-02 | 2024-11-26 | 하버 바이오메드 (상하이) 컴퍼니 리미티드 | Pd-l1 및 cd40을 표적화하는 항원 결합 단백질, 이의 제조 방법 및 응용 |
| JP2025540505A (ja) * | 2022-11-15 | 2025-12-12 | ティージェイ バイオファーマ （シャンハイ） カンパニー， リミテッド | 抗ｐｄ－ｌ１ナノボディ |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2720160T3 (es) * | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| WO2011043194A1 (en) | 2009-10-09 | 2011-04-14 | Semiconductor Energy Laboratory Co., Ltd. | Semiconductor device and method for manufacturing the same |
| EP3096782A4 (en) * | 2014-01-21 | 2017-07-26 | Medlmmune, LLC | Compositions and methods for modulating and redirecting immune responses |
| KR102003754B1 (ko) * | 2014-07-03 | 2019-07-25 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
| RU2753902C2 (ru) * | 2014-11-20 | 2021-08-24 | Ф.Хоффманн-Ля Рош Аг | Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1 |
| CN105777906B (zh) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
| CN106939047B (zh) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| JP6730466B2 (ja) | 2016-06-13 | 2020-07-29 | アイ−エムエービー バイオファーマ ユーエス リミテッド | 抗ｐｄ−ｌ１抗体およびその使用 |
| CN107488229B (zh) * | 2016-06-13 | 2020-11-17 | 天境生物科技(上海)有限公司 | Pd-l1抗体及其用途 |
| CN108777906B (zh) | 2018-06-25 | 2020-06-16 | 珠海惠尔益电子科技有限公司 | 一种双灯组变焦电路及头灯 |
| WO2020020307A1 (en) * | 2018-07-25 | 2020-01-30 | I-Mab Biopharma Co., Ltd. | Anti-cd73 anti-pd-l1 bispecific antibodies |
| MX2021006379A (es) * | 2018-11-30 | 2021-10-13 | Abl Bio Inc | Anticuerpos biespecificos anti-pd-l1/anti-4-1bb y usos de los mismos. |
-
2019
- 2019-03-29 US US16/610,071 patent/US11220546B2/en active Active
- 2019-03-29 MY MYPI2020003980A patent/MY188237A/en unknown
- 2019-03-29 CA CA3086434A patent/CA3086434C/en active Active
- 2019-03-29 AU AU2019241339A patent/AU2019241339B2/en active Active
- 2019-03-29 PE PE2020001301A patent/PE20210377A1/es unknown
- 2019-03-29 SG SG11202006008WA patent/SG11202006008WA/en unknown
- 2019-03-29 CN CN201980003429.7A patent/CN110891975B/zh active Active
- 2019-03-29 JP JP2019553005A patent/JP7124257B2/ja active Active
- 2019-03-29 BR BR112020019827-7A patent/BR112020019827A2/pt unknown
- 2019-03-29 MX MX2020007842A patent/MX2020007842A/es unknown
- 2019-03-29 UA UAA202005634A patent/UA125918C2/uk unknown
- 2019-03-29 EP EP19769368.2A patent/EP3589660A4/en active Pending
- 2019-03-29 EA EA202091590A patent/EA202091590A1/ru unknown
- 2019-03-29 WO PCT/CN2019/080458 patent/WO2019185029A1/en not_active Ceased
- 2019-03-29 KR KR1020197031498A patent/KR102177931B1/ko active Active
- 2019-03-29 KR KR1020207032104A patent/KR102475106B1/ko active Active
-
2020
- 2020-06-29 IL IL275734A patent/IL275734B/en unknown
- 2020-08-02 PH PH12020551173A patent/PH12020551173A1/en unknown
- 2020-08-28 CL CL2020002223A patent/CL2020002223A1/es unknown
-
2021
- 2021-12-28 US US17/563,502 patent/US20220119531A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA202091590A1 (ru) | 2021-01-21 |
| CN110891975B (zh) | 2023-11-10 |
| BR112020019827A2 (pt) | 2021-01-05 |
| CA3086434A1 (en) | 2019-10-03 |
| IL275734B (en) | 2022-06-01 |
| EP3589660A1 (en) | 2020-01-08 |
| JP2020518233A (ja) | 2020-06-25 |
| IL275734A (en) | 2020-08-31 |
| KR20190128716A (ko) | 2019-11-18 |
| PH12020551173A1 (en) | 2021-05-31 |
| CN110891975A (zh) | 2020-03-17 |
| JP7124257B2 (ja) | 2022-08-24 |
| WO2019185029A1 (en) | 2019-10-03 |
| UA125918C2 (uk) | 2022-07-06 |
| AU2019241339B2 (en) | 2021-08-12 |
| MX2020007842A (es) | 2020-09-25 |
| KR20200130747A (ko) | 2020-11-19 |
| NZ758371A (en) | 2024-10-25 |
| CA3086434C (en) | 2024-01-09 |
| EP3589660A4 (en) | 2021-04-07 |
| AU2019241339A1 (en) | 2019-11-14 |
| US20220119531A1 (en) | 2022-04-21 |
| MY188237A (en) | 2021-11-24 |
| KR102177931B1 (ko) | 2020-11-13 |
| PE20210377A1 (es) | 2021-03-02 |
| SG11202006008WA (en) | 2020-07-29 |
| KR102475106B1 (ko) | 2022-12-08 |
| US11220546B2 (en) | 2022-01-11 |
| US20200157222A1 (en) | 2020-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002223A1 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
| CO2018013500A2 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| CL2019001756A1 (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
| PH12019502785A1 (en) | Anti trbc1 antigen binding domains | |
| PE20191031A1 (es) | ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| PY1829572A (es) | Dominios de unión a antígeno humanizados y métodos de uso | |
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| CO2018010547A2 (es) | Receptores quiméricos y métodos de uso de los mismos | |
| IL265541B1 (en) | Bispecific antibodies and compositions comprising thereof for treating cancer | |
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
| IL299221A (en) | Cd3 binding antibodies | |
| AR106991A1 (es) | Anticuerpos neutralizantes del virus de inmunodeficiencia humana | |
| HRP20201022T1 (hr) | Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba | |
| EA201791270A1 (ru) | Модифицированные april-связывающие антитела | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| PE20130580A1 (es) | Proteinas terapeuticas de union a dll4 | |
| EA201691225A1 (ru) | Антитело к pd-1, его антигенсвязывающий фрагмент и их медицинское применение | |
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| PE20142322A1 (es) | Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc | |
| MX2020007406A (es) | Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo. | |
| PE20201171A1 (es) | Anticuerpos de cadena pesada que se unen a cd22 |